Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 1/2 4Phase 2 3Phase EARLY_PHASE1 1

Status

Unknown 6Withdrawn 3Completed 3Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Ovarian Neoplasms 1HER2-negative Breast Cancer 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × pamiparib × Clear all
NCT05044871 2025-06-08

BRIGHT

Tongji Hospital

Phase 2 Completed
108 enrolled
Gynecologic

Ovarian Neoplasms

NCT03427814 2024-10-26

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

BeiGene

Phase 2 Completed
136 enrolled 16 charts
Gastrointestinal

Stomach Neoplasms

NCT03575065 2024-10-26

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

BeiGene

Phase 2 Completed
88 enrolled 17 charts
Breast

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡